Safety Needles

BD AutoShield™ Duo Pen Needle

About BD AutoShield™ Duo Pen Needle | BD AutoShield™ Duo Pen Compatibility
For Materials Management | For Hospital Pharmacy

Peace of mind from passive protection after use

BD AutoShield™ Duo is the only pen needle that passively covers the front and back needles, eliminating exposure after use.

Studies show that both ends of a pen needle are contaminated after use^1,2, so both ends of the needle require safety features³
Colored shields on both the front and back-end needles provide visual and tactile confirmation of safety
BD AutoShield™ Duo is the only pen needle that fits every diabetes pen⁴, so you get the highest level of protection - no matter which pen you use

View online in-service

The only needle that provides a “no pinch” injection technique for nurses' safety.

AutoShield Duo

Peace of mind and total protection.

BD AutoShield™ Duo is the only needle that eliminates “pinch up” for injection and provides passive protection after use.


Attach Duo to any pen your facility uses	Inject straight in at a 90 degree angle - no second hand, no pinch up technique. The front shield automatically protects from injury when removing from the skin.	Remove the needle from the pen. A second shield automatically protects you from the back end needle.	Dispose in a sharps collector.

Email BD or call 1-888-356-3241 to:

Request more information about how BD AutoShield™ Duo can benefit your facility
Schedule a demonstration
Learn how BD’s training and in-service support can aid staff uptake

BD AutoShield™ Duo Pen Needle

Catalog No.	NDC No.	Needle Size	Quantity
329515	08290-3295-15	30 G x 3/16 in. (5mm)	100/Box

¹ Kreugel G, Keers JC, Jongbloed A, Wolffenbuttel BHR. Randomized trial on the influence of the length of
two insulin pen needles on glycemic control and patient preference in obese patients with diabetes. Diab
Tech Ther 2011;13(7): DOI: 10.1089/dia.2011.0010.

² Kreugel G, Beijer HJM, Kerstens MN, Maaten ter JC, Sluiter WJ, Boot BS. Influence of needle size for subcutaneous insulin administration on metabolic control and patient acceptance. European Diabetes Nursing. 2007: Vol. 4 No. 2.

³ Kreugel G, Keers JC, Jongbloed A, et al. The influence of needle length on glycemic control and patient preference in obese diabetic patients. Diabetes. 2009; 58(S1): 440.

⁴ Frid, A, et. al: New injection recommendations for patients with diabetes. Diabetes & Metabolism 2010;36: S3-S18.

⁵ OSHA Bloodborne Pathogen Standard: 29 CFR §1910.1030(c) (1)(iv), paragraphs (A) and (B).

⁶ Gibney MA, Arce CH, Byron KJ, Hirsch LJ. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin. 2010; 26 (6): 1519–1530.

⁷ Karges B, Boehm BO, Karges W. Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Diabet Med. 2005 Oct;22(10):1444-5.

⁸ Data on file at BD as of August 2011.